What to Know About Discontinuing Alzheimer's Drugs

a group of various pills

Yolanda Pons / FOAP / Getty Images

Picture this; You're the main caregiver for your loved one, and you want to provide the best care possible for him. That includes considering which medications he's receiving and whether they should be continued or if the time has come to discontinue their use.

Of course, these decisions are made in partnership with his physician, but after the doctor provides the rationale for their recommendations, she will probably ask you for your opinion. So, what to do? First, acknowledge that this can be a stressful decision to make. And second, learn all you can about what research has demonstrated about this decision.

Benefits of Medications

Medications are prescribed for people with dementia with the hope of slowing down the progression or even improving the cognitive functioning for a time. Research has shown that there is often some benefit from these medications, although they don't cure the disease.

Treating Alzheimer's Disease

There are two types of medications prescribed to treat Alzheimer's disease.

Cholinesterase Inhibitors

  • Aricept (donepezil): Approved for mild, moderate, and severe Alzheimer's
  • Exelon (rivastigmine): Approved for mild to moderate Alzheimer's
  • Razadyne (galantamine): Approved for mild to moderate Alzheimer's

N-Methyl D-Aspartate (NMDA) Antagonists

  • Namenda (memantine) is another medication that is used to try to slow down the progression of dementia and is approved for use in moderate to severe Alzheimer's disease.

Why Discontinue Medications

Consider discontinuing medications when one or both of the following two factors arise:

  • Side Effects: If there are too many side effects or they diminish the quality of life for the person, strong consideration should be given towards discontinuing the medication.
  • No Benefit: If the patient or loved one has been on the medication for quite some time and now her dementia has progressed to the late stages, physicians and pharmacists will sometimes recommend discontinuing the medication if there is no observed benefit. This decision may, at times, be made when a person elects hospice care, but at other times it is considered as an option simply if the perceived benefit is little or none.

How Medications Should Be Discontinued

Medications should be discontinued gradually and one at a time. When discontinuing medications, monitor your loved one or patient closely. If you start to see a significant decline in cognition or behavior, you may want to ask the physician to restart the medication.

If a notable decline in functioning develops after discontinuation, restarting the medication sooner rather than later may increase the likelihood of the person returning close to his previous (prior to stopping the medicine) level of functioning.

What Research Has Shown

There has not been a lot of research conducted on stopping medications for the treatment of dementia. However, some research seems to indicate that people whose dementia medications were discontinued declined in cognition and behavior more quickly.

One study compared nursing home residents with dementia who were receiving cholinesterase inhibitor medications to treat dementia to other nursing home residents whose cholinesterase inhibitors were discontinued.

The researchers found that those whose medications were discontinued experienced more behavioral challenges such as repetitive questioning and frequent health concerns. This group also participated less in activities compared to those who were still on their medication.

Make an Educated Decision

There can be a range of results after medications for dementia have been discontinued. At times, there has been a decline in functioning as described above after discontinuing the medications, and there have also been other situations where there was very little change, if any, after medications for dementia were discontinued. The key is for family members is to be aware that the possibility for decline exists and to make this decision together with their loved one's physician.

A Word From Verywell

One physician proposed the following question when considering whether or not to discontinue medication for the treatment of Alzheimer's disease:

"Is there anything going on in this life that is good and might be missed if the medication is stopped?" (Dr. Gene Lammers)

The decision to continue or stop medication in Alzheimer's disease should be one that is based on each individual's preferences and functioning. Perhaps considering the above question will be helpful to clarify your next steps as you seek your loved one's best interests.

Was this page helpful?

Article Sources

Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial policy to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Atri A. Current and Future Treatments in Alzheimer's Disease. Semin Neurol. 2019;39(2):227-240.

  2. Casey DA, Antimisiaris D, O'Brien J. Drugs for Alzheimer's disease: are they effective?P T. 2010;35(4):208–211.

  3. Sharma K. Cholinesterase inhibitors as Alzheimer's therapeutics (Review)Mol Med Rep. 2019;20(2):1479–1487. doi:10.3892/mmr.2019.10374

  4. Knowles J. Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical and economic outcomesCore Evid. 2006;1(3):195–219.

  5. Khoury R, Rajamanickam J, Grossberg GT. An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmineTher Adv Drug Saf. 2018;9(3):171–178. doi:10.1177/2042098617750555

  6. Hager K, Baseman AS, Nye JS, et al. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease [published correction appears in Neuropsychiatr Dis Treat. 2014;10:1997]. Neuropsychiatr Dis Treat. 2014;10:391–401. Published 2014 Feb 21. doi:10.2147/NDT.S57909

  7. Olivares D, Deshpande VK, Shi Y, et al. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's diseaseCurr Alzheimer Res. 2012;9(6):746–758. doi:10.2174/156720512801322564

  8. Kuns B, Varghese D. Memantine. [Updated 2019 Oct 9]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK500025/

  9. Soler A, Amer G, Leiva A, et al. Continuation versus discontinuation of treatment for severe dementia: randomized, pragmatic, open-label, clinical trial to evaluate the efficacy of continuing drug treatment in patients with severe dementia (STOP-DEM). BMC Geriatr. 2019;19(1):101. Published 2019 Apr 11. doi:10.1186/s12877-019-1122-2

  10. Massoud F, Gauthier S. Update on the pharmacological treatment of Alzheimer's diseaseCurr Neuropharmacol. 2010;8(1):69–80. doi:10.2174/157015910790909520

  11. Lim EY, Yang DW, Kim JS, Cho AH. Safety and Efficacy of Anti-dementia Agents in the Extremely Elderly Patients with DementiaJ Korean Med Sci. 2018;33(19):e133. Published 2018 Apr 13. doi:10.3346/jkms.2018.33.e133

  12. Daiello LA, Ott BR, Lapane KL, Reinert SE, Machan JT, Dore DD. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Am J Geriatr Pharmacother. 2009;7(2):74-83.

  13. Peyro saint-paul L, Martin J, Gaillard C, et al. [Sudden Discontinuation of Anti-dementia Drugs in Moderate and Severe Alzheimer's Disease in a Residency for Dependent Elderly People: a Longitudinal Descriptive Pilot Study]. Therapie. 2015;70(4):313-9.

Additional Reading